Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 28;11:1336. doi: 10.3389/fphar.2020.01336

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Steijns, Bracke, Renard, De Backer, Sips, Debunne, Wynendaele, Verbeke, De Spiegeleer and Campens

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Inhibitory effect of refametinib on ERK activation in murine myocardial and aortic tissue. Refametinib strongly suppressed pERK levels in myocardial (A) and aortic (B) tissue of mice treated for 7 days with 50 mg/kg/day refametinib supplemented drinking water compared to untreated mice. pERK expression was calculated based on the total ERK expression after which values were normalized to the mean value of untreated mice. Western blots of pERK and total ERK levels in myocardial (C) and aortic (D) tissue at indicated doses of refametinib supplemented drinking water. Samples represent biological replicates. * independent two-sample t-test, p = 0.0169, *** independent two-sample t-test, p < 0.001.